MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation

The discovery of mitochondrial-derived peptides has opened an exciting new chapter in therapeutic medicine, and MOTS-c stands out as perhaps the most promising candidate for clinical development. This review by Zheng, Wei, and Wang, published in Frontiers in Endocrinology, assessed the full therapeutic potential of MOTS-c across multiple disease areas.

The authors conducted a comprehensive literature review examining MOTS-c's effects on metabolic regulation, cardiovascular function, bone health, neurological protection, and inflammatory conditions. They also evaluated the practical considerations for translating MOTS-c research into therapeutic applications.

The evidence reveals MOTS-c as a remarkably versatile therapeutic peptide. Beyond its well-established metabolic benefits — improving insulin sensitivity and glucose metabolism — MOTS-c shows protective effects against cardiovascular disease, osteoporosis, neurodegeneration, and chronic inflammatory conditions. Its mechanism of action through AMPK activation and mitochondrial-nuclear communication gives it influence over fundamental cellular processes.

This broad therapeutic profile positions MOTS-c as a uniquely valuable tool in the peptide therapy arsenal. The authors note that its natural origin as an endogenous peptide, combined with its multi-system benefits, makes it especially well-suited for addressing the complex, interconnected health challenges that emerge with aging. The review calls for accelerated clinical development to bring MOTS-c's benefits to patients.